



National Association of Pharmacy Regulatory Authorities  
Association nationale des organismes de réglementation de la pharmacie

**Revised National Drug Scheduling Factors**      **Approved by NAPRA Board of Directors April 2008**  
For implementation September 2008 NDSAC meeting

## **SCHEDULE I FACTORS**

- I-1: The need for the drug is identifiable only by the prescribing practitioner.
- I-2: Use of the drug requires adjunctive therapy or evaluation.
- I-3: Appropriate use of the drug may produce dependency.
- I-4: Serious adverse drug reactions are known to occur or have a recognized potential to occur at normal therapeutic dosage levels.
- I-5: There is a narrow margin of safety between the therapeutic and toxic dosages of the drug, either in the general population or in identified subpopulations, or in patients with multiple medical problems.
- I-6: Serious drug interactions are known to occur.
- I-7: Use of the drug has contributed to, or is likely to contribute to, the development of resistant strains of microorganisms.
- I-8: The medicinal ingredient is new, or is being used for a new indication that is not amenable to self-treatment, and the consequences of widespread use are not adequately established